Compare ASTRAZENECA PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 94.0 53.7 175.0% View Chart
P/BV x 26.5 4.7 566.3% View Chart
Dividend Yield % 0.0 10.1 -  

Financials

 ASTRAZENECA PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
ASTRAZENECA PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,2783,549 36.0%   
Low Rs8831,301 67.8%   
Sales per share (Unadj.) Rs228.4511.4 44.7%  
Earnings per share (Unadj.) Rs10.461.3 16.9%  
Cash flow per share (Unadj.) Rs16.374.0 22.0%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs98.8927.8 10.6%  
Shares outstanding (eoy) m25.0016.60 150.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.7 99.7%   
Avg P/E ratio x104.239.6 263.4%  
P/CF ratio (eoy) x66.432.8 202.8%  
Price / Book Value ratio x10.92.6 418.4%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m27,00840,257 67.1%   
No. of employees `0001.41.1 119.6%   
Total wages/salary Rs m1,5351,313 117.0%   
Avg. sales/employee Rs Th4,210.97,486.7 56.2%   
Avg. wages/employee Rs Th1,132.21,157.6 97.8%   
Avg. net profit/employee Rs Th191.1897.2 21.3%   
INCOME DATA
Net Sales Rs m5,7108,490 67.3%  
Other income Rs m123244 50.2%   
Total revenues Rs m5,8338,734 66.8%   
Gross profit Rs m4631,482 31.2%  
Depreciation Rs m147211 69.8%   
Interest Rs m00-   
Profit before tax Rs m4381,514 28.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m179563 31.8%   
Profit after tax Rs m2591,017 25.5%  
Gross profit margin %8.117.5 46.5%  
Effective tax rate %40.837.1 110.0%   
Net profit margin %4.512.0 37.9%  
BALANCE SHEET DATA
Current assets Rs m3,20915,343 20.9%   
Current liabilities Rs m2,0701,960 105.6%   
Net working cap to sales %20.0157.6 12.7%  
Current ratio x1.67.8 19.8%  
Inventory Days Days7249 148.4%  
Debtors Days Days3528 122.8%  
Net fixed assets Rs m7901,209 65.4%   
Share capital Rs m50166 30.1%   
"Free" reserves Rs m2,41915,235 15.9%   
Net worth Rs m2,46915,401 16.0%   
Long term debt Rs m00-   
Total assets Rs m4,60517,595 26.2%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.5 256.9%   
Return on assets %5.65.8 97.3%  
Return on equity %10.56.6 158.8%  
Return on capital %17.710.3 172.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3001,636 18.3%   
Fx outflow Rs m2,0154,368 46.1%   
Net fx Rs m-1,715-2,732 62.8%   
CASH FLOW
From Operations Rs m88-1,304 -6.7%  
From Investments Rs m-9412,697 -0.7%  
From Financial Activity Rs mNA-301 0.0%  
Net Cashflow Rs m-611,093 -0.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 15.7 1.0 1,570.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   12,856 28,591 45.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 19, 2019 01:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - CIPLA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS